

Product datasheet for TP724192

Human MDR-1 (72-113) Protein, hFc Tag

Product data:

Product Type: Recombinant Proteins

Description: Human MDR-1 (72-113) Protein, hFc Tag

Expression Host: HFK293

Tag: C-Human Fc

Predicted MW: The protein has a predicted molecular mass of 30.9 kDa after removal of the signal peptide.

The apparent molecular mass of MDR-1-hFc is approximately 35-55 kDa due to glycosylation.

OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com

The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie **Purity:**

blue staining.

Reconstitution Method: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants

before lyophilization.

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended Storage:

for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).

Lyophilized proteins are shipped at ambient temperature.

Stability: 12 months from date of despatch

Summary: The membrane-associated protein encoded by this gene is a member of the superfamily of

> ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is an ATP-dependent drug efflux pump for xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug

> accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs. This protein also functions as a transporter in the blood-brain barrier. Mutations in this gene are associated with colchicine resistance and Inflammatory bowel disease 13. Alternative splicing and the use of alternative promoters results in multiple

transcript variants. [provided by RefSeq, Feb 2017]

